Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate- specific antigen working group
Clinical Trials, Phase II as Topic
Consensus Development Conferences, NIH as Topic
Through this consensus conference, we believe we have developed practical guidelines for using PSA as a measurement of outcome. Furthermore, the use of common standards is important as we determine which agents should progress to randomized trials which will use survival as an end point.